Almonty Industries rises as market reacts to biotech sector gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2024
0mins
Should l Buy ALM?
Source: Newsfilter
Almonty Industries Inc saw a price increase of 9.01% as it crossed above its 5-day SMA, reflecting positive momentum in the market.
The rise in Almonty’s stock is amid a broader market reaction to Sarepta Therapeutics' significant three-year study results from the EMBARK study, which demonstrated the efficacy of Elevidys in treating Duchenne muscular dystrophy. This news has sparked investor optimism in the biopharmaceutical sector, potentially leading to increased capital inflow into related industries.
This positive sentiment in the biotech sector may encourage investors to seek opportunities in companies like Almonty, which could benefit from the overall market enthusiasm and increased focus on healthcare investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALM
Wall Street analysts forecast ALM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALM is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.700
Low
12.00
Averages
12.00
High
12.00
Current: 12.700
Low
12.00
Averages
12.00
High
12.00
About ALM
Almonty Industries Inc. is a diversified and global producer of tungsten concentrate. The Company is engaged in mining, processing and shipping tungsten concentrate from its Panasqueira Mine in Portugal. It also has a significant molybdenum resource on a separate property adjacent to the tungsten orebody at the Sangdong Mine. Its additional development projects include the Valtreixal Project in northwestern Spain and Los Santos Mine in western Spain. The Panasqueira Mine is located in Covilha, Castelo Branco, Portugal. The Sangdong Mine is located at Sangdong in the south-eastern Korean Peninsula, approximately 170 km east-southeast of Seoul, South Korea. The Valtreixal Mine is a potential open pit operation, and is located in the northwest part of the Zamora province, in the Castilla de Leon region of Spain. It also operates Woulfe, whose properties are located in Gangwon Province, Republic of Korea, and whose operations relate primarily to the development of the Sangdong Project.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Almonty Industries Stock Signals Warning for Momentum Investors
- Analyst Rating Upgrade: DA Davidson analyst Griffin Bryan maintained a Buy rating on Almonty Industries and raised the price target from $12 to $18, indicating confidence in the company's future growth potential.
- Strong Stock Performance: Almonty Industries' stock has surged approximately 39% over the past month, reaching a 52-week high of $13.82, reflecting market recognition of its potential value.
- High RSI Value: The Relative Strength Index (RSI) for Almonty Industries stands at 74.1, suggesting that the stock may be overbought, prompting investors to exercise caution.
- Recent Price Fluctuation: Despite the positive analyst outlook, Almonty Industries' shares fell 0.2% to close at $13.36 on Wednesday, indicating the complexity of market sentiment.
See More
Global Silver Market Faces Intensifying Supply Deficit
- Supply-Demand Imbalance: The global silver market is facing its fifth consecutive year of supply deficit, with industrial consumption outpacing mine production, leading to silver prices surpassing $100 per ounce, attracting investor interest in companies capable of rapid production.
- Monetizing Historic Stockpiles: Americore Resources is evaluating options to monetize historic surface stockpiles at its Trinity Silver Project in Nevada, potentially containing approximately 400,000 ounces of silver in oxide and 365,000 ounces in sulfide, aiming for near-term cash flow through expedited processing pathways.
- Capital Flow Shift: The global mining industry has shifted towards brownfield development, with capital now flowing primarily into existing mine infrastructure rather than speculative greenfield projects, with brownfield restarts delivering production timelines 50% to 70% faster, providing structural advantages for companies with historic stockpiles.
- Strategic Land Expansion: Americore has aggressively expanded its land position over recent months, now controlling approximately 22,700 acres of prospective ground, which is expected to triple its resource base to 36 million ounces of silver equivalent, enhancing future production potential.
See More
Global Silver Market Faces Continued Supply Deficit
- Silver Supply Shortage: The global silver market is facing its fifth consecutive year of supply deficit, with industrial consumption consistently outpacing mine production, leading to market tightness that impacts production plans and profitability for related companies.
- Strategic Mineral Supply Chain Pressure: Governments are prioritizing domestic processing capacity and international partnerships to reduce dependencies, with capital rotating towards companies capable of rapidly converting existing assets, reflecting a heightened focus on supply chain security.
- Americore Resources Strategy: Americore Resources is evaluating options to monetize historic surface stockpiles at its Trinity Silver Project in Nevada, potentially unlocking around 400,000 ounces of silver, leveraging the current silver price of approximately $100 per ounce to generate near-term cash flow.
- Mako Mining Resource Update: Mako Mining reported an updated mineral resource estimate for its Moss Mine in Arizona, showing 679,000 gold equivalent ounces, with steady production expected to commence later this quarter, further solidifying its market position.
See More
DaVita Reports Strong Q4 Earnings, Shares Surge 21.7%
- Strong Earnings Report: DaVita's Q4 earnings per share of $3.40 exceeded analyst expectations of $3.16, demonstrating robust profitability that enhances market confidence in the company's future performance.
- Sales Beat Estimates: The company reported quarterly sales of $3.620 billion, surpassing the analyst consensus of $3.497 billion, indicating strong competitive positioning and a rebound in customer demand that is expected to drive future revenue growth.
- Significant Stock Surge: DaVita's shares jumped 21.7% to $135.26 on Tuesday, reflecting a positive investor reaction to the financial results, which may attract further institutional interest in the stock.
- Price Target Increase: Barclays raised its price target for DaVita from $143 to $158, indicating analysts' optimistic outlook on the company's growth potential, which could further propel the stock price upward.
See More
Almirall's Seysara® Approved in China for Acne Treatment
- Regulatory Approval: Almirall's Seysara® (sarecycline hydrochloride) has received approval from China's National Medical Products Administration, becoming the first oral antibiotic specifically developed for moderate to severe acne treatment, expected to launch in 2026 to meet significant patient demand.
- Clinical Efficacy: Clinical trials in the US and China have demonstrated Seysara®'s significant efficacy and favorable safety profile, effectively reducing inflammatory lesion counts and showing results as early as three weeks into treatment, thereby improving patients' quality of life.
- Market Collaboration: Almirall has entered into an exclusive commercialization agreement with Sinomune Pharmaceutical in China, ensuring rapid market entry for the new drug and enhancing the company's market share in the dermatology sector in China.
- Strategic Commitment: This approval underscores Almirall's ongoing commitment to addressing unmet medical needs in dermatology globally, aiming to leverage innovative treatments to solidify its leadership position in medical dermatology.
See More
Sarepta Therapeutics Reports Significant Three-Year Study Results
- Clinical Trial Results: Sarepta Therapeutics reported significant three-year results from the EMBARK study, showing that patients treated with Elevidys demonstrated statistically significant efficacy in motor function assessments, leading to a 9.8% stock price increase to $23.20, indicating enhanced competitiveness in Duchenne muscular dystrophy treatment.
- Positive Market Reaction: Following the release of favorable clinical data, there was a surge in demand for Sarepta's shares, reflecting investor optimism about the biopharmaceutical sector's outlook, which may attract more capital into the industry.
- Industry Impact: Sarepta's success could inspire other biopharmaceutical companies to increase investments in rare disease research and development, thereby fostering innovation and growth across the sector.
- Investor Confidence Boost: The success story of Sarepta may bolster investor confidence in biotech stocks, particularly as market conditions continue to favor increased focus on the healthcare sector.
See More
Almonty Industries Stock Signals Warning for Momentum Investors
- Analyst Rating Upgrade: DA Davidson analyst Griffin Bryan maintained a Buy rating on Almonty Industries and raised the price target from $12 to $18, indicating confidence in the company's future growth potential.
- Strong Stock Performance: Almonty Industries' stock has surged approximately 39% over the past month, reaching a 52-week high of $13.82, reflecting market recognition of its potential value.
- High RSI Value: The Relative Strength Index (RSI) for Almonty Industries stands at 74.1, suggesting that the stock may be overbought, prompting investors to exercise caution.
- Recent Price Fluctuation: Despite the positive analyst outlook, Almonty Industries' shares fell 0.2% to close at $13.36 on Wednesday, indicating the complexity of market sentiment.
See More
Global Silver Market Faces Intensifying Supply Deficit
- Supply-Demand Imbalance: The global silver market is facing its fifth consecutive year of supply deficit, with industrial consumption outpacing mine production, leading to silver prices surpassing $100 per ounce, attracting investor interest in companies capable of rapid production.
- Monetizing Historic Stockpiles: Americore Resources is evaluating options to monetize historic surface stockpiles at its Trinity Silver Project in Nevada, potentially containing approximately 400,000 ounces of silver in oxide and 365,000 ounces in sulfide, aiming for near-term cash flow through expedited processing pathways.
- Capital Flow Shift: The global mining industry has shifted towards brownfield development, with capital now flowing primarily into existing mine infrastructure rather than speculative greenfield projects, with brownfield restarts delivering production timelines 50% to 70% faster, providing structural advantages for companies with historic stockpiles.
- Strategic Land Expansion: Americore has aggressively expanded its land position over recent months, now controlling approximately 22,700 acres of prospective ground, which is expected to triple its resource base to 36 million ounces of silver equivalent, enhancing future production potential.
See More
Global Silver Market Faces Continued Supply Deficit
- Silver Supply Shortage: The global silver market is facing its fifth consecutive year of supply deficit, with industrial consumption consistently outpacing mine production, leading to market tightness that impacts production plans and profitability for related companies.
- Strategic Mineral Supply Chain Pressure: Governments are prioritizing domestic processing capacity and international partnerships to reduce dependencies, with capital rotating towards companies capable of rapidly converting existing assets, reflecting a heightened focus on supply chain security.
- Americore Resources Strategy: Americore Resources is evaluating options to monetize historic surface stockpiles at its Trinity Silver Project in Nevada, potentially unlocking around 400,000 ounces of silver, leveraging the current silver price of approximately $100 per ounce to generate near-term cash flow.
- Mako Mining Resource Update: Mako Mining reported an updated mineral resource estimate for its Moss Mine in Arizona, showing 679,000 gold equivalent ounces, with steady production expected to commence later this quarter, further solidifying its market position.
See More
DaVita Reports Strong Q4 Earnings, Shares Surge 21.7%
- Strong Earnings Report: DaVita's Q4 earnings per share of $3.40 exceeded analyst expectations of $3.16, demonstrating robust profitability that enhances market confidence in the company's future performance.
- Sales Beat Estimates: The company reported quarterly sales of $3.620 billion, surpassing the analyst consensus of $3.497 billion, indicating strong competitive positioning and a rebound in customer demand that is expected to drive future revenue growth.
- Significant Stock Surge: DaVita's shares jumped 21.7% to $135.26 on Tuesday, reflecting a positive investor reaction to the financial results, which may attract further institutional interest in the stock.
- Price Target Increase: Barclays raised its price target for DaVita from $143 to $158, indicating analysts' optimistic outlook on the company's growth potential, which could further propel the stock price upward.
See More
Almirall's Seysara® Approved in China for Acne Treatment
- Regulatory Approval: Almirall's Seysara® (sarecycline hydrochloride) has received approval from China's National Medical Products Administration, becoming the first oral antibiotic specifically developed for moderate to severe acne treatment, expected to launch in 2026 to meet significant patient demand.
- Clinical Efficacy: Clinical trials in the US and China have demonstrated Seysara®'s significant efficacy and favorable safety profile, effectively reducing inflammatory lesion counts and showing results as early as three weeks into treatment, thereby improving patients' quality of life.
- Market Collaboration: Almirall has entered into an exclusive commercialization agreement with Sinomune Pharmaceutical in China, ensuring rapid market entry for the new drug and enhancing the company's market share in the dermatology sector in China.
- Strategic Commitment: This approval underscores Almirall's ongoing commitment to addressing unmet medical needs in dermatology globally, aiming to leverage innovative treatments to solidify its leadership position in medical dermatology.
See More
Sarepta Therapeutics Reports Significant Three-Year Study Results
- Clinical Trial Results: Sarepta Therapeutics reported significant three-year results from the EMBARK study, showing that patients treated with Elevidys demonstrated statistically significant efficacy in motor function assessments, leading to a 9.8% stock price increase to $23.20, indicating enhanced competitiveness in Duchenne muscular dystrophy treatment.
- Positive Market Reaction: Following the release of favorable clinical data, there was a surge in demand for Sarepta's shares, reflecting investor optimism about the biopharmaceutical sector's outlook, which may attract more capital into the industry.
- Industry Impact: Sarepta's success could inspire other biopharmaceutical companies to increase investments in rare disease research and development, thereby fostering innovation and growth across the sector.
- Investor Confidence Boost: The success story of Sarepta may bolster investor confidence in biotech stocks, particularly as market conditions continue to favor increased focus on the healthcare sector.
See More
